Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical Group, a manufacturer and supplier of branded generic and anti-cancer pharmaceuticals in China, has reported that it is seeking approval to manufacture and sell products containing zanamivir, one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.
Subscribe to our email newsletter
GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is reportedly the only pharmaceutical company in mainland China that has such a license.
Xiaojin Yin, senior vice president of R&D at Simcere Pharmaceutical Group, said: “We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug.”